SYNDAX PHARMACEUTICALS INC's ticker is SNDX and the CUSIP is 87164F105. A total of 166 filers reported holding SYNDAX PHARMACEUTICALS INC in Q2 2023. The put-call ratio across all filers is 2.02 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $34,088,211 | -35.4% | 2,347,673 | -6.9% | 0.03% | -32.6% |
| Q2 2023 | $52,783,704 | +3.4% | 2,521,916 | +4.4% | 0.04% | -8.5% |
| Q1 2023 | $51,035,510 | -12.9% | 2,416,454 | +5.0% | 0.05% | -20.3% |
| Q4 2022 | $58,592,163 | +47.8% | 2,302,246 | +39.5% | 0.06% | +51.3% |
| Q3 2022 | $39,645,000 | +752.2% | 1,649,795 | +210.7% | 0.04% | +680.0% |
| Q4 2017 | $4,652,000 | -58.2% | 531,028 | -44.2% | 0.01% | -54.5% |
| Q3 2017 | $11,137,000 | -16.4% | 951,898 | -0.2% | 0.01% | -21.4% |
| Q2 2017 | $13,325,000 | +1882.9% | 953,862 | +917.1% | 0.01% | +1300.0% |
| Q4 2016 | $672,000 | -88.4% | 93,783 | -75.6% | 0.00% | -83.3% |
| Q3 2016 | $5,818,000 | +10.9% | 383,776 | -28.6% | 0.01% | 0.0% |
| Q2 2016 | $5,247,000 | -12.2% | 537,545 | +16.6% | 0.01% | 0.0% |
| Q1 2016 | $5,978,000 | – | 460,892 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aisling Capital Management LP | 1,025,000 | $24,631,000 | 16.36% |
| Kynam Capital Management, LP | 2,272,915 | $54,618,000 | 11.51% |
| Frazier Life Sciences Management, L.P. | 3,412,838 | $82,010,000 | 6.32% |
| Foresite Capital Management IV, LLC | 690,000 | $16,581,000 | 5.33% |
| Paradigm Biocapital Advisors LP | 1,085,142 | $26,076,000 | 3.48% |
| ACUTA CAPITAL PARTNERS, LLC | 324,614 | $7,800,000 | 3.36% |
| COMMODORE CAPITAL LP | 738,110 | $17,737,000 | 2.85% |
| SPHERA FUNDS MANAGEMENT LTD. | 822,696 | $19,769,000 | 2.74% |
| Avidity Partners Management LP | 5,586,900 | $134,253,000 | 2.73% |
| HealthCor Management, L.P. | 859,240 | $20,648,000 | 2.58% |